Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disorder with genetic heterogeneity. Up to three loci are involved in this disease, PKD1 on chromosome 16pl3.3, PKD2 on 4q21, and a third locus of unknown location. Here we report the existence of locus heterogeneity for this disease in the Argentinian population by performing linkage analysis on 12 families of Caucasian origin. Eleven families showed linkage to PKDI1 and one family showed linkage to PKD2. Two recombinants in the latter family placed the locus PKD2 proximal to D4S1563, in agreement with data recendy published on the cloning of this gene. Analysis of clinical data suggests a milder ADPKD phenotype for the PKD2 family.
Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common inherited disorders in humans, affecting 1 in 400 to 2400 in the Caucasian population. This disease is mainly characterised by progressive cystic dilatation of the renal tubules and other organs like the liver, spleen, and pancreas and is associated with both cardiac abnormalities and intracranial aneurysms.' In Argentina, ADPKD is the underlying cause of renal failure in 7.2% of patients with end stage renal disease (ESRD). Approximately 51% of PKD patients enter renal failure by the age of 70. 2 ADPKD is genetically heterogeneous, with evidence of three different loci involved. The first ADPKD locus to be mapped was PKD1, which was localised to 16p13.3.' Since then, many authors have reported several families unlinked to chromosome 16. A second ADPKD locus, PKD2, has been linked to 4q12-22. 4 Recently, families with ADPKD unlinked to PKD1 or PKD2 loci have been described.6 PKD1 accounts for approximately 85% of ADPKD and is a more severe condition than PKD2, with an average age of ESRD showing that linkage heterogeneity is present in our group of families. PKD 1 was identified as the disease locus in 11 families (conditional probability of linkage higher than 0.9 in each case). The maximum multipoint lod score under heterogeneity (Zmax=12.05) was obtained by placing PKD1 in the interval close to the markers (D16S283-D16S663-D16S291).
Only one family (16012) showed statistically significant evidence of non-linkage to PKD1, with a conditional probability of 0.00 (table 1) . The analysis of chromosome 4 markers showed positive linkage to the PKD2 locus (fig 2) . In this PKD2 family, two recombinant subjects between the closely positioned markers D4S 1534 and D4S1563 were studied in detail.
Analysis of patients II.2 and 11.9 with markers D4S1542, D4S2929, and JSTG3 (data taken from Genethon data base) placed the gene proximal to marker D4S 1563 (fig 1) , where the gene was recently identified.'0 CLINICAL ANALYSIS A total of 142 subjects were studied for the purpose of this report. Fifty-eight subjects were affected, 60 blood relatives were unaffected (at risk subjects), and 24 were spouses. No significant differences were seen in the number of male/female ADPKD patients (24 males v 34 females, X2 =0.0197, NS). We investigated 12 families affected with autosomal dominant polycystic kidney disease, 11 of which were linked to PKD 1. The finding of only one family linked to PKD2 does not allow us to estimate the frequency of this form in our population. In the PKD 1 families, all members over 30 years of age with affected relatives and a PKD1 associated haplotype had detectable cysts. No member entered ESRD below the age of 30. Twelve subjects (30%) developed chronic renal failure at a mean age of 46.2 years. However, members without the associated PKD1 haplotype did not enter ESRD or have cysts. Twelve subjects at risk between 0 and 30 years of age (nine between 0 and 10 years, two between 10 and 20, and one between 20 and 30) carried the affected haplotype with-out evidence of cysts on ultrasound examination at the time of the study (table 2).
All members of the PKD2 family carrying a disease associated haplotype had cysts, independent of their age (table 2) . No member of the PKD2 family needed dialysis or transplantation, even when studied at advanced ages. Our assessment of 21 subjects in four generations of this large family is consistent with previous observations that PKD2 patients present a more benign clinical form in comparison to PKD1 patients.7 In regard to the presence of cysts as related to age, PKD2 patients develop cysts earlier than PKD 1 patients. Further investigation is needed to determine whether the severity of the disease and age related expression are different between PKD1 and PKD2 types.
Based on the recently published sequences of both PKD1 and PKD2, we are currently identifying different mutations and their clinical correlates in the Argentine PKD population. However, reported mutations for PKD1 are heterogeneous and complex enough to suggest that linkage analysis will continue to be the most useful approach for the presymptomatic diagnosis of PKD in Argentina.
